碳酸锂致肾性尿崩症的研究进展  

Research progress of nephrogenic diabetes insipidus induced by carbonate lithium

作　　者：朱航毅 赵一璟 史雨清 杨昱 王昆 Zhu Hangyi;Zhao Yijing;Shi Yuqing;Yang Yu;Wang Kun(Nanjing Medical University Graduate School,Nanjing 211166,China;Department of Endocrinology and Metabolism,the Affiliated Jiangning Hospital of Nanjing Medical University,Nanjing 211100,China)

机构地区：[1]南京医科大学研究生院,211166 [2]南京医科大学附属江宁医院内分泌科,211100

出　　处：《国际内分泌代谢杂志》2022年第6期485-488,共4页International Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金(81870542);江苏省中医药管理局国家中医临床研究基地(江苏省中医药研究院)开放课题项目(JD2019SZXYB08);南京市卫生科技发展专项资金项目(YKK18208)。

摘　　要：碳酸锂是治疗甲状腺功能亢进症的药物,肾性尿崩症(NDI)是其常见的肾脏不良反应。碳酸锂对肾脏的影响与锂的累计剂量和暴露的持续时间有关,长期使用锂盐治疗可能会导致不可逆的肾脏疾病。碳酸锂可通过降低水通道蛋白2(AQP2)基因的转录水平、诱导集合管重构、引起肾脏线粒体功能障碍等途径引起NDI。近年来本病的治疗方法从传统治疗手段到新型药物治疗策略,取得了一定的研究进展。本文就碳酸锂诱导NDI的发病机制和治疗策略等方面的研究进展予以综述。Lithium carbonate is a therapeutic drug for hyperthyroidism.The most common renal side effect is nephrogenic diabetes insipidus.The effect of lithium carbonate on kidney is related to the duration of exposure and the cumulative dose of lithium.Long-term use of lithium will lead to irreversible kidney injury.Lithium carbonate can induce nephrogenic diabetes insipidus by reducing the transcription level of Aquaporin 2(AQP2)gene,leading to collecting duct remodeling,and causing renal mitochondrial dysfunction.In recent years,some progress has been appeared in the treatment of this disease from traditional treatment to new drug treatment strategy.This article reviews the research progress on the pathogenesis and treatment of nephrogenic diabetes insipidus induced by lithium carbonate.

关 键 词：碳酸锂 甲状腺功能亢进症 肾性尿崩症 水通道蛋白2 

分 类 号：R969.3[医药卫生—药理学]